HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IVF
INVO Fertility, Inc.
There isn't enough reported data to score IVF yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IVF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
IVF's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IVF PE Valuation
IVF has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IVF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| -- |
Analysts expect IVF's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
IVF has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus IVF down 190%.
IVF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$284,774.40 | +$30,193.92 |
| Q2 2023 | -$365,414.40 | -$36,622.08 |
| Q1 2023 | -$400,896.00 | -$99,751.68 |
| Q4 2022 | -$414,720.00 | -$104,359.68 |
| Q3 2022 | -$314,968.32 | +$353,191.68 |
| Q2 2022 | -$328,792.32 | +$394,663.68 |
| Q1 2022 | -$301,144.32 | +$469,313.28 |
| Q4 2021 | -$310,360.32 | +$492,353.28 |
IVF is still losing money, but far less than before: $284,774.40 per share over the past year, against $802,713.60 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IVF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over IVF on profitability, with a higher operating margin.
IVF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +17% |
| Q1 2026 | $2M | +23% |
| Q4 2025 | $1.6M | -7.7% |
| Q3 2025 | $1.8M | +23% |
| Q2 2025 | $1.9M | +1.5% |
| Q1 2025 | $1.6M | +3.9% |
| Q4 2024 | $1.7M | +24% |
| Q3 2024 | $1.4M | +47% |
IVF's revenue is recovering but still below its 2021 peak: $2M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -59% | +101 points |
| Q1 2026 | -79% | +966 points |
| Q4 2025 | -89% | +143 points |
| Q3 2025 | -93% | -2.3 points |
| Q2 2025 | -160% | -57 points |
| Q1 2025 | -1045% | -985 points |
| Q4 2024 | -232% | -123 points |
| Q3 2024 | -91% | +0.2 points |
IVF's operating margin was −59% last quarter, up 101 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
IVF has the stronger cash trend. Its trailing FCF is down 35% versus its history, compared with HIMS at down 84%.
IVF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $13.4K | +$709.6K |
| Q3 2025 | -$1.8M | -$1.1M |
| Q2 2025 | -$1.7M | -$215.7K |
| Q1 2025 | -$3.6M | -$3.2M |
| Q4 2024 | -$696.3K | +$93.6K |
| Q3 2024 | -$640.8K | +$714.7K |
| Q4 2023 | -$789.9K | +$214.1K |
| Q3 2023 | -$1.4M | +$295.3K |
IVF has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IVF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IVF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -103 shares |
| 1 year | +276% | +456 shares |
| 3 years | +2288% | +595 shares |
| 5 years | +5545% | +610 shares |
IVF has 621 diluted shares, up 276% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IVF Net Leverage
IVF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IVF Weekly Momentum
As of the close on Nov 12, 2026: $2.69.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IVF PE vs Healthcare Sector
IVF has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IVF Weekly Moving Averages
As of the close on Nov 12, 2026: $2.69.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IVF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $3.42 | $2.69 | -21% |
IVF has the edge over HIMS on returns for 2026, with the stronger performance.